For immediate release |
27 January 2014 |
Futura Medical plc
("Futura" or "the Company")
US Roll-out of PET500
Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology, notes the announcement from Ansell Limited in connection with the commercial launch of PET500, which is set to become available in stores throughout the USA and to be available online.
Ansell has exclusive worldwide rights to PET500, which it is distributing under the name EPIC as part of its Lifestyles® brand. EPIC® is a topical spray that combines Futura's DermaSys® AquaFree delivery system with a mild topical anaesthetic. EPIC is designed to delay male ejaculation and to take effect quickly.
Ansell has also launched a combination product, called UPHORIA, in which EPIC has been packaged with an existing Ansell product, LifeStyles EXCITE™, a personal lubricant designed to promote enhanced stimulation and sensitivity for women.
Ansell's media announcement is available at the following link: http://www.futuramedical.com/archive/press_release/EPIC_and_UPHORIA.pdf
Elsewhere in its portfolio, Futura is continuing in discussions with further potential commercial partners ahead of the launch of its novel condom, CSD500, which is being licensed on a regional basis.
James Barder, Futura's Chief Executive, commented: "We are delighted that PET500 will become available during the next few weeks in a large number of stores throughout the USA. We are also continuing discussions in connection with further territorial distribution agreements for our novel condom, CSD500, and look forward to the product's launch during 2014."
For any further information please contact:
Futura Medical plc |
+ 44 (0) 1483 685 670 |
James Barder, Chief Executive Officer Mail to: James.Barder@futuramedical.com |
|
Cenkos Securities plc |
|
Bobbie Hilliam |
+44 (0) 20 7397 8900 |
Buchanan |
+ 44 (0) 20 7466 5000 |
Mark Court / Fiona Henson / Sophie Cowles |
Notes to editors:
About Futura Medical plc
Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.